BACKGROUND: The impact of osmotic therapies on brain metabolism has not been extensively studied in humans. The authors examined if mannitol treatment of raised intracranial pressure will result in an improvement in brain metabolism together with the expected drop in intracranial pressure (ICP). METHODS: This is a retrospective review of prospectively collected data. Twenty episodes of raised ICP (>20 mm Hg) resistant to standard therapy that required infusions of mannitol were studied in 12 comatose patients with multimodality monitoring including ICP, PbtO(2) and microdialysis. The authors compared mean arterial blood pressure, ICP, cerebral perfusion pressure, PbtO(2), brain lactate, pyruvate and glucose using cerebral microdialysis, for 3 h preceding and 4 h after hyperosmolar therapy. Time-series data were analysed using a multivariable general linear model utilising generalised estimating equations for model estimation to account for within-subjects and between-subjects variations over time. RESULTS: 20% mannitol solution (1 g/kg) was administered at the discretion of the attending neurointensivist. ICP decreased 30 min (from 27 ± 13 to 19 ± 16 mm Hg, p<0.001) and cerebral perfusion pressure increased 45 min (from 73 ± 18 to 85 ± 22 mm Hg, p=0.002) after the start of mannitol infusions, whereas mean arterial blood pressure and PbtO(2) did not change significantly. The peak lactate-pyruvate ratio was recorded at the time of initiating osmotherapy (44 ± 20) with an 18% decrease over 2 h following mannitol therapy (35 ± 16; p=0.002). Brain glucose remained unaffected. CONCLUSIONS: Mannitol effectively reduces ICP and appeared to benefit brain metabolism as measured by the lactate-pyruvate ratio.
BACKGROUND: The impact of osmotic therapies on brain metabolism has not been extensively studied in humans. The authors examined if mannitol treatment of raised intracranial pressure will result in an improvement in brain metabolism together with the expected drop in intracranial pressure (ICP). METHODS: This is a retrospective review of prospectively collected data. Twenty episodes of raised ICP (>20 mm Hg) resistant to standard therapy that required infusions of mannitol were studied in 12 comatosepatients with multimodality monitoring including ICP, PbtO(2) and microdialysis. The authors compared mean arterial blood pressure, ICP, cerebral perfusion pressure, PbtO(2), brain lactate, pyruvate and glucose using cerebral microdialysis, for 3 h preceding and 4 h after hyperosmolar therapy. Time-series data were analysed using a multivariable general linear model utilising generalised estimating equations for model estimation to account for within-subjects and between-subjects variations over time. RESULTS: 20% mannitol solution (1 g/kg) was administered at the discretion of the attending neurointensivist. ICP decreased 30 min (from 27 ± 13 to 19 ± 16 mm Hg, p<0.001) and cerebral perfusion pressure increased 45 min (from 73 ± 18 to 85 ± 22 mm Hg, p=0.002) after the start of mannitol infusions, whereas mean arterial blood pressure and PbtO(2) did not change significantly. The peak lactate-pyruvate ratio was recorded at the time of initiating osmotherapy (44 ± 20) with an 18% decrease over 2 h following mannitol therapy (35 ± 16; p=0.002). Brain glucose remained unaffected. CONCLUSIONS:Mannitol effectively reduces ICP and appeared to benefit brain metabolism as measured by the lactate-pyruvate ratio.
Authors: Mauro Oddo; Daniele Poole; Raimund Helbok; Geert Meyfroidt; Nino Stocchetti; Pierre Bouzat; Maurizio Cecconi; Thomas Geeraerts; Ignacio Martin-Loeches; Hervé Quintard; Fabio Silvio Taccone; Romergryko G Geocadin; Claude Hemphill; Carole Ichai; David Menon; Jean-François Payen; Anders Perner; Martin Smith; José Suarez; Walter Videtta; Elisa R Zanier; Giuseppe Citerio Journal: Intensive Care Med Date: 2018-03-02 Impact factor: 17.440
Authors: Keri L H Carpenter; Marek Czosnyka; Ibrahim Jalloh; Virginia F J Newcombe; Adel Helmy; Richard J Shannon; Karol P Budohoski; Angelos G Kolias; Peter J Kirkpatrick; Thomas Adrian Carpenter; David K Menon; Peter J Hutchinson Journal: Front Neurol Date: 2015-02-18 Impact factor: 4.003
Authors: Raimund Helbok; Pedro Kurtz; Michael J Schmidt; Morgan R Stuart; Luis Fernandez; Sander E Connolly; Kiwon Lee; Erich Schmutzhard; Stephan A Mayer; Jan Claassen; Neeraj Badjatia Journal: Crit Care Date: 2012-11-27 Impact factor: 9.097
Authors: Mario Kofler; Alois Schiefecker; Ronny Beer; Florian Sohm; Gregor Broessner; Paul Rhomberg; Peter Lackner; Bettina Pfausler; Claudius Thomé; Erich Schmutzhard; Raimund Helbok Journal: Neurocrit Care Date: 2016-10 Impact factor: 3.210